Baloxavir Marboxil
2 NDCs across 1 manufacturer|0 Generic,2 Brand
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 24, 2018, and the first generic was approved Jun 17, 2026. FDA's Orange Book lists 4 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $1 million on Baloxavir Marboxil across 7,723 claims for 7,548 beneficiaries.
Baloxavir Marboxil is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $161.95 to $161.97 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$161.95 – $161.97
per EA
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing BALOXAVIR MARBOXIL
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
XOFLUZA 80 MG TABLET | $161.9683 per EA | — |
XOFLUZA 40 MG TABLET | $161.9466 per EA | — |
Frequently Asked Questions
When did Baloxavir Marboxil become available as a generic?
FDA approved the first generic Baloxavir Marboxil (ANDA) on Jun 17, 2026. The Orange Book currently lists 4 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Baloxavir Marboxil?
In 2024, Medicare Part D spent $1 million on Baloxavir Marboxil across 7,723 claims for 7,548 beneficiaries.
How many Baloxavir Marboxil products are on the market?
The Baloxavir Marboxil drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Baloxavir Marboxil?
NADAC reference prices for Baloxavir Marboxil range from $161.9466 to $161.9683 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Baloxavir Marboxil?
1 manufacturer lists Baloxavir Marboxil in NADAC. Ranked by number of NDCs, the largest are Genentech, Inc. (2).